Skip to main content

Table 2 Frequencies (median percentages [95% confidence intervals]*) of activated cells within lymphocyte subsets in Burkitt's lymphoma patients and healthy control donors

From: Selective activation of TCR-γδ+ cells in endemic Burkitt's lymphoma

Subset   Healthy controls BL patients Difference P(T)*
TCR-αβ+** CD25+ 13.5 [9.3 to 16.9] 8.0 [4.9 to 11.1] -5.0 [-8.6 to -0.6] 0.04
TCR-αβ+ CD69+ 4.1 [1.2 to 8.5] 2.2 [1.1 to 4.6] -1.2 [-4.2 to 0.8] 0.20
TCR-αβ+ HLA-DR + 12.6 [7.6 to 21.1] 20.2 [11. 4 to 30.0] 7.2 [-0.6 to 16.9] 0.07
TCR-αβ+ CD95+ 36.7 [29.1 to 44.8] 45.4 [16.2 to 58.4] 6.2 [-12.2 to 20.6] 0.40
TCR-γδ+ CD25+ 1.6 [0.9 to 4.6] 5.8 [2.6 to 11. 9] 3.6 [1.0 to 8.1] 0.007
TCR-γδ+ CD69+ 7.5 [2.0 to 14.6] 8.9 [4.0 to 13.3] 1.4 [-4.0 to 8.1] 0.61
TCR-γδ+ HLA-DR + 33.3 [16.7 to 50.0] 54.8 [39.6 to 67.8] 22.7 [8.8 to 36.2] 0.003
TCR-γδ+ CD95+ 42.5 [32.5 to 58.3] 68.8 [30.4 to 89.0] 21.3 [-1.7 to 41.0] 0.10
  1. * The statistical significance of differences in medians was calculated by the Mann-Whitney rank-sum test. Confidence intervals for median differences were calculated using CIA 2.0 software [1].
  2. ** Defined as CD3+ TCR-γδ-negative cells